For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

The value proposition in contemporary health and disease care: A study published in the Canadian Journal of Cardiology into the cost-effectiveness of the use of semaglutide in overweight or obese ...

New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...